Title: Tumor-promoting and pro-angiogenic effects of roxarsone via VEGFR2/PLCγ/PKC signaling.
Journal: Chemico-biological interactions 20180825
Title: Why are most phospholipidosis inducers also hERG blockers?
Journal: Archives of toxicology 20171201
Title: The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells.
Journal: Oncotarget 20170411
Title: Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension.
Journal: Circulation research 20150828
Title: Caveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species.
Journal: Free radical biology & medicine 20140801
Title: NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20140801
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Journal: The Biochemical journal 20130415
Title: Resveratrol ameliorates high-glucose-induced hyperpermeability mediated by caveolae via VEGF/KDR pathway.
Journal: Genes & nutrition 20130301
Title: Vitamin D improves the angiogenic properties of endothelial progenitor cells.
Journal: American journal of physiology. Cell physiology 20121101
Title: Leptin induces tube formation in first-trimester extravillous trophoblast cells.
Journal: European journal of obstetrics, gynecology, and reproductive biology 20120901
Title: Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Journal: Bioorganic & medicinal chemistry 20120715
Title: VEGF regulates antidepressant effects of lamotrigine.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120601
Title: N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
Journal: Bioorganic & medicinal chemistry 20120401
Title: Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.
Journal: Journal of molecular graphics & modelling 20120201
Title: N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.
Journal: Bioorganic & medicinal chemistry 20120115
Title: Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.
Journal: Ophthalmic research 20120101
Title: Normalization of the lymph node T cell stromal microenvironment in lpr/lpr mice is associated with SU5416-induced reduction in autoantibodies.
Journal: PloS one 20120101
Title: The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
Journal: PloS one 20120101
Title: SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation.
Journal: PloS one 20120101
Title: Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase.
Journal: PloS one 20120101
Title: Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Journal: Current cancer drug targets 20111101
Title: Clinical experience with antiangiogenic therapy in leukemia.
Journal: Current cancer drug targets 20111101
Title: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111101
Title: [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Journal: Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20110901
Title: Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1.
Journal: Developmental cell 20110816
Title: SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
Journal: Neurochemical research 20110801
Title: Peptide-directed highly selective targeting of pulmonary arterial hypertension.
Journal: The American journal of pathology 20110601
Title: Virtual screening and further development of novel ALK inhibitors.
Journal: Bioorganic & medicinal chemistry 20110515
Title: Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism.
Journal: American journal of physiology. Heart and circulatory physiology 20110401
Title: Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416.
Journal: Archives of ophthalmology (Chicago, Ill. : 1960) 20110301
Title: The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension.
Journal: Respiration; international review of thoracic diseases 20110101
Title: SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.
Journal: Molecular vision 20110101
Title: A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors.
Journal: PloS one 20110101
Title: Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition.
Journal: Neuroscience 20101124
Title: Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633.
Journal: Cancer letters 20101001
Title: Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
Journal: American journal of respiratory and critical care medicine 20100901
Title: Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100901
Title: Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
Journal: Bioorganic & medicinal chemistry 20100715
Title: Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity.
Journal: Bioorganic & medicinal chemistry 20100615
Title: The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.
Journal: Bioorganic & medicinal chemistry letters 20100515
Title: Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
Journal: Bioorganic & medicinal chemistry 20100515
Title: TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes.
Journal: Chemico-biological interactions 20100415
Title: CREB activation mediates VEGF-A's protection of neurons and cerebral vascular endothelial cells.
Journal: Journal of neurochemistry 20100401
Title: Vascular endothelial growth factor is involved in mediating increased de novo hippocampal neurogenesis in response to traumatic brain injury.
Journal: Journal of neurotrauma 20100301
Title: Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
Journal: Journal of medicinal chemistry 20100225
Title: Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema.
Journal: American journal of respiratory and critical care medicine 20100215
Title: Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.
Journal: Bioorganic & medicinal chemistry 20100215
Title: Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke.
Journal: Stroke 20100201
Title: ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.
Journal: Gastroenterology 20100101
Title: Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997) 20100101
Title: Synthesis and radiopharmacological investigation of 3-[4'-[(18)F]fluorobenzylidene]indolin-2-one as possible tyrosine kinase inhibitor.
Journal: Bioorganic & medicinal chemistry 20091115
Title: Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.
Journal: Experimental eye research 20091101
Title: Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
Journal: Bioorganic & medicinal chemistry 20091015
Title: Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Journal: Nature chemical biology 20091001
Title: Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats.
Journal: American journal of physiology. Regulatory, integrative and comparative physiology 20090701
Title: Genetic evidence for a noncanonical function of seryl-tRNA synthetase in vascular development.
Journal: Circulation research 20090605
Title: VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Journal: Journal of neuroimmunology 20090430
Title: Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
Journal: Cancer biology & therapy 20090315
Title: VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent.
Journal: Experimental cell research 20090310
Title: Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
Journal: Pediatric blood & cancer 20090201
Title: VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
Journal: International immunopharmacology 20090101
Title: Ligation or cross-linking of CD40 has different effects on AGS gastric cancer cells.
Journal: Cellular immunology 20090101
Title: Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Journal: Cancer letters 20081108
Title: Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
Journal: British journal of cancer 20080520
Title: Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Journal: Bioorganic & medicinal chemistry 20080515
Title: Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080401
Title: Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants.
Journal: American journal of physiology. Lung cellular and molecular physiology 20080101
Title: Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
Journal: Journal of translational medicine 20080101
Title: Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
Journal: Human reproduction update 20080101
Title: Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase.
Journal: Japanese journal of ophthalmology 20080101
Title: Development of an intravenous formulation of SU010382 (prodrug of SU5416, an anti-angiogenesis agent).
Journal: PDA journal of pharmaceutical science and technology 20080101
Title: VEGF modulation of retinal pigment epithelium resistance.
Journal: Experimental eye research 20071201
Title: Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis.
Journal: American journal of physiology. Regulatory, integrative and comparative physiology 20071001
Title: Effect of chemical stabilizers of hypoxia-inducible factors on early lung development.
Journal: American journal of physiology. Lung cellular and molecular physiology 20070901
Title: Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
Journal: Oncogene 20070531
Title: A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.
Journal: Investigational new drugs 20070401
Title: Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Journal: Circulation research 20070330
Title: Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles.
Journal: Bioorganic & medicinal chemistry letters 20070315
Title: Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis.
Journal: Anti-cancer drugs 20070301
Title: A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Journal: Cancer chemotherapy and pharmacology 20070201
Title: [Clinical importance of angiogenesis and angiogenic factors in oncohematology].
Journal: Wiadomosci lekarskie (Warsaw, Poland : 1960) 20070101
Title: Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.
Journal: Leukemia & lymphoma 20061201
Title: Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Journal: Journal of the American Society of Nephrology : JASN 20061101
Title: Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.
Journal: American journal of physiology. Lung cellular and molecular physiology 20061001
Title: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
Journal: The Journal of clinical endocrinology and metabolism 20061001
Title: Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416.
Journal: Bioorganic & medicinal chemistry 20061001
Title: Inhibition of RET tyrosine kinase by SU5416.
Journal: Journal of molecular endocrinology 20061001
Title: [Recent advances in the study of pharmacological activities and solid-phase synthesis of indoles and their analogues].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20060801
Title: Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo.
Journal: International journal of cancer 20060715
Title: A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
Journal: Investigational new drugs 20060701
Title: VEGF-C promotes survival in podocytes.
Journal: American journal of physiology. Renal physiology 20060701
Title: Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity.
Journal: American journal of physiology. Gastrointestinal and liver physiology 20060701
Title: Anti-angiogenic and anti-HER therapy.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20060701
Title: Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Journal: Journal of medicinal chemistry 20060601
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Title: Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Journal: American journal of clinical oncology 20060401
Title: Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.
Journal: Toxicology in vitro : an international journal published in association with BIBRA 20060301
Title: Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Journal: Expert opinion on emerging drugs 20060301
Title: A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
Journal: Japanese journal of clinical oncology 20060201
Title: Clinical implications for vascular endothelial growth factor in the lung: friend or foe?
Journal: Respiratory research 20060101
Title: Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.
Journal: Bioorganic & medicinal chemistry letters 20051215
Title: Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Journal: Cancer chemotherapy and pharmacology 20051201
Title: Nerve growth factor-induced migration of endothelial cells.
Journal: The Journal of pharmacology and experimental therapeutics 20051201
Title: A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
Journal: British journal of cancer 20051017
Title: Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model.
Journal: Radiology 20051001
Title: Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.
Journal: Journal of medicinal chemistry 20050825
Title: Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050701
Title: In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Journal: Cancer research 20050615
Title: [Potential pharmacological treatments for diabetic retinopathy].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20050601
Title: [Medications for diabetic macular edema].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20050601
Title: Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050315
Title: C-kit as a target in the treatment of acute myelogenous leukemia.
Journal: Current hematology reports 20050101
Title: Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20050101
Title: Emphysema: an autoimmune vascular disease?
Journal: Proceedings of the American Thoracic Society 20050101
Title: Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Journal: International journal of radiation oncology, biology, physics 20041115
Title: SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway.
Journal: Biochemical and biophysical research communications 20041112
Title: c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism.
Journal: Cancer research 20040915
Title: Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Journal: European journal of pharmacology 20040913
Title: Vascular endothelial growth factor in diabetes induced early retinal abnormalities.
Journal: Diabetes research and clinical practice 20040901
Title: Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040901
Title: SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Journal: Journal of hepatology 20040801
Title: Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Journal: Leukemia research 20040701
Title: Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040615
Title: Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040605
Title: The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1).
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040501
Title: The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation.
Journal: The American journal of pathology 20040501
Title: [Lung cancer: molecular targeting therapy].
Journal: Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040501
Title: New cancer therapeutics: target-specific in, cytotoxics out?
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401
Title: Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401
Title: N-acetylcysteine treatment protects against VEGF-receptor blockade-related emphysema.
Journal: COPD 20040401
Title: Antiangiogenic therapy for von Hippel-Lindau disease.
Journal: JAMA 20040225
Title: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040201
Title: Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
Journal: Cancer chemotherapy and pharmacology 20040101
Title: Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040101
Title: Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
Journal: Urologic oncology 20040101
Title: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Journal: Cancer research 20031215
Title: SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20031015
Title: Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.
Journal: Cancer research 20031015
Title: The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity.
Journal: Cancer research 20031015
Title: Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20030901
Title: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Journal: Blood 20030801
Title: Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
Journal: Journal of the National Cancer Institute 20030716
Title: Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade.
Journal: American journal of respiratory cell and molecular biology 20030701
Title: Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
Journal: American journal of ophthalmology 20030701
Title: SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Journal: Cancer research 20030701
Title: SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Journal: Molecular cancer therapeutics 20030701
Title: Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Journal: The Journal of pharmacology and experimental therapeutics 20030601
Title: Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601
Title: Potential inhibitors of angiogenesis. Part I: 3-(imidazol-4(5)-ylmethylene)indolin-2-ones.
Journal: Journal of enzyme inhibition and medicinal chemistry 20030601
Title: Potential inhibitors of angiogenesis. Part II: 3-(azolylmethylene)-2,3-dihydrobenzo[b]furan-2-ones.
Journal: Journal of enzyme inhibition and medicinal chemistry 20030601
Title: Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro.
Journal: Experimental cell research 20030501
Title: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
Journal: The Journal of clinical investigation 20030501
Title: Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20030501
Title: Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Journal: Cancer 20030415
Title: [From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
Journal: Il Giornale di chirurgia 20030401
Title: Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
Journal: Journal of medicinal chemistry 20030327
Title: Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse.
Journal: Reproduction (Cambridge, England) 20030301
Title: Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin.
Journal: Neoplasia (New York, N.Y.) 20030301
Title: [Perspectives on the oncologist pharmacopoeia].
Journal: Bulletin du cancer 20030101
Title: Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.
Journal: BMC cancer 20030101
Title: Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Journal: Medical oncology (Northwood, London, England) 20030101
Title: Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
Journal: Journal of medicinal chemistry 20021219
Title: Synthetic lethality: killing cancer with cancer.
Journal: Journal of the National Cancer Institute 20021120
Title: Zebrafish: a preclinical model for drug screening.
Journal: Assay and drug development technologies 20021101
Title: SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Journal: Blood 20021015
Title: Inhibitors of the vascular endothelial growth factor receptor.
Journal: Hematology/oncology clinics of North America 20021001
Title: New drugs in acute myeloid leukemia.
Journal: Current oncology reports 20020901
Title: Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
Journal: Ophthalmology 20020901
Title: Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20020901
Title: Targeting vascular endothelial growth factor in colorectal cancer.
Journal: Oncology (Williston Park, N.Y.) 20020801
Title: A novel dihydroxanthenone, AGI-B4 with inhibition of VEGF-induced endothelial cell growth.
Journal: The Journal of antibiotics 20020701
Title: Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Journal: The Journal of surgical research 20020601
Title: Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study.
Journal: British journal of cancer 20020520
Title: CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs.
Journal: Pediatric research 20020501
Title: Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
Journal: The Journal of biological chemistry 20020419
Title: Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315
Title: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315
Title: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315
Title: Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Journal: Molecular cancer therapeutics 20020301
Title: SU5416 delays wound healing through inhibition of TGF-beta 1 activation.
Journal: Cancer biology & therapy 20020101
Title: New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.
Journal: Oncology 20020101
Title: Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
Journal: Angiogenesis 20020101
Title: Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice.
Journal: Cold Spring Harbor symposia on quantitative biology 20020101
Title: Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma.
Journal: Angiogenesis 20020101
Title: Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20011001
Title: Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival.
Journal: The Kobe journal of medical sciences 20010801
Title: Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS.
Journal: Journal of pharmaceutical and biomedical analysis 20010701
Title: Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.
Journal: Blood 20010701
Title: Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas.
Journal: Journal of neuro-oncology 20010701
Title: Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Journal: Cancer research 20010501
Title: Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010501
Title: [Tumor angiogenesis and tumor angiogenesis inhibitors].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20010501
Title: The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Journal: Blood 20010301
Title: The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Journal: The oncologist 20010101
Title: Endothelial survival factors as targets for antineoplastic therapy.
Journal: Cancer journal (Sudbury, Mass.) 20010101
Title: Role of angiogenesis inhibitors in acute myeloid leukemia.
Journal: Cancer journal (Sudbury, Mass.) 20010101
Title: Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Journal: Journal of medicinal chemistry 20000713
Title: New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Journal: Journal of medicinal chemistry 20000615
Title: Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Journal: Journal of medicinal chemistry 19991216
Title: Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Journal: Journal of medicinal chemistry 19980702
Title: Fong TA, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res, 1999, 59(1), 99-106.
Title: Vajkoczy P, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia, 1999, 1(1), 31-41.
Title: Happé CM, et al. Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats.Am J Physiol Lung Cell Mol Physiol. 2016 Jun 1;310(11):L1088-97.
Title: Izquierdo-Garcia JL, et al. Metabolic Reprogramming in the Heart and Lung in a Murine Model of Pulmonary Arterial Hypertension. Front Cardiovasc Med. 2018 Aug 15;5:110.
